Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets ;

Efficacy: This product is mainly used to treat human immunodeficiency virus-1 (HIV-1) infection.
Dosage and Administration:
Treatment with Acontinib should be initiated by a physician with rich experience in HIV disease management. The specific dosage and course of medication should be arranged by the specialist. Before starting this product, the hepatitis B virus infection should be tested, the patient’s renal function should be assessed, and the serum phosphorus level should also be assessed for patients with chronic kidney disease. Dosage of Acontinib: Adults and adolescents aged 12 years and above and weighing at least 35 kg: once a day, one tablet each time, take with food, do not chew, crush or break it apart. Elderly: For elderly patients, there is no need to adjust the dosage of Acontinib. Pediatric population: The safety and efficacy of Acontinib in children under 12 years of age or weighing <35 kg have not been determined.
Contraindications:
Allergic to this product is prohibited. Children are prohibited. Pregnancy is prohibited. Drinking is cautious. Driving is cautious. Lactation is cautious. Hepatic and renal insufficiency is cautious.
Related dosage forms:
Acontinib tablets